[go: up one dir, main page]

MA46337B1 - Composé de pyridine - Google Patents

Composé de pyridine

Info

Publication number
MA46337B1
MA46337B1 MA46337A MA46337A MA46337B1 MA 46337 B1 MA46337 B1 MA 46337B1 MA 46337 A MA46337 A MA 46337A MA 46337 A MA46337 A MA 46337A MA 46337 B1 MA46337 B1 MA 46337B1
Authority
MA
Morocco
Prior art keywords
pyridine compound
pharmaceutically acceptable
acceptable salt
relates
compound
Prior art date
Application number
MA46337A
Other languages
English (en)
Other versions
MA46337A (fr
Inventor
Hiroaki Inagaki
Yoshihiro Shibata
Hidenori Namiki
Hideaki Kageji
Kiyoshi Nakayama
Yasuyuki Kaneta
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MA46337A publication Critical patent/MA46337A/fr
Publication of MA46337B1 publication Critical patent/MA46337B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne un composé ayant une action inhibitrice de la kinase ret ou un sel pharmaceutiquement acceptable de celui-ci, utile dans le traitement de maladies telles que le cancer. En particulier, l'invention concerne un composé représenté par la formule générale (i) suivante telle que définie dans la description : (i) ou un sel pharmaceutiquement acceptable de celui-ci.
MA46337A 2016-09-29 2017-09-28 Composé de pyridine MA46337B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016191725A JP2018052878A (ja) 2016-09-29 2016-09-29 ピリジン化合物
PCT/GB2017/052913 WO2018060714A1 (fr) 2016-09-29 2017-09-28 Composé de pyridine

Publications (2)

Publication Number Publication Date
MA46337A MA46337A (fr) 2019-08-07
MA46337B1 true MA46337B1 (fr) 2021-04-30

Family

ID=60020249

Family Applications (2)

Application Number Title Priority Date Filing Date
MA46337A MA46337B1 (fr) 2016-09-29 2017-09-28 Composé de pyridine
MA054910A MA54910A (fr) 2016-09-29 2017-09-28 Sels de pyridine et procédé

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA054910A MA54910A (fr) 2016-09-29 2017-09-28 Sels de pyridine et procédé

Country Status (33)

Country Link
US (2) US10851092B2 (fr)
EP (2) EP3828178A1 (fr)
JP (2) JP2018052878A (fr)
KR (1) KR102520543B1 (fr)
CN (2) CN110036007B (fr)
AU (2) AU2017335242C1 (fr)
BR (1) BR112019006047A2 (fr)
CA (1) CA3035860A1 (fr)
CL (1) CL2019000844A1 (fr)
CO (1) CO2019004034A2 (fr)
CY (1) CY1123988T1 (fr)
DK (1) DK3519398T3 (fr)
EA (1) EA037103B1 (fr)
EC (1) ECSP19030134A (fr)
ES (1) ES2868748T3 (fr)
HR (1) HRP20210447T1 (fr)
HU (1) HUE054824T2 (fr)
IL (1) IL265630B (fr)
LT (1) LT3519398T (fr)
MA (2) MA46337B1 (fr)
MD (1) MD3519398T2 (fr)
MX (1) MX2019003747A (fr)
PE (1) PE20190805A1 (fr)
PH (1) PH12019500480A1 (fr)
PL (1) PL3519398T3 (fr)
PT (1) PT3519398T (fr)
RS (1) RS61640B1 (fr)
SG (1) SG11201901937WA (fr)
SI (1) SI3519398T1 (fr)
SM (1) SMT202100315T1 (fr)
UA (1) UA123964C2 (fr)
WO (1) WO2018060714A1 (fr)
ZA (1) ZA201902232B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079140A1 (fr) 2015-11-02 2017-05-11 Blueprint Medicines Corporation Inhibiteurs de ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
WO2019143977A1 (fr) 2018-01-18 2019-07-25 Array Biopharma Inc. Composés de pyrrolo[2,3-d]pyrimidines substitués utilisés en tant qu'inhibiteurs de la kinase ret
EP3740486A1 (fr) 2018-01-18 2020-11-25 Array Biopharma, Inc. Composés de pyrazolyl[4,3-c]pyridine substitués utilisés en tant qu'inhibiteurs de la kinase ret
JP7422084B2 (ja) 2018-04-03 2024-01-25 ブループリント メディシンズ コーポレイション Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
EP3942045A1 (fr) 2019-03-21 2022-01-26 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
MX2022005991A (es) * 2019-11-18 2022-06-17 Chugai Pharmaceutical Co Ltd Farmaco combinado.
CN113121524B (zh) 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
JP7461605B2 (ja) * 2020-02-20 2024-04-04 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 キノリン系化合物
WO2021164741A1 (fr) * 2020-02-20 2021-08-26 南京明德新药研发有限公司 Composé de bisamide de phényle
WO2021243192A1 (fr) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Formes solide de pralsetinib
WO2022238706A1 (fr) 2021-05-14 2022-11-17 Bp Asset Viii, Inc. Inhibiteur de ret pour le traitement du cancer médullaire de la thyroïde à altération de ret ou du cancer du poumon non à petites cellules à altération de ret
WO2023239422A2 (fr) 2021-10-22 2023-12-14 University Of Houston System Méthodes et compositions pour traiter une lésion inflammatoire chronique, une métaplasie, une dysplasie et des cancers des tissus épithéliaux
CN115090331B (zh) * 2022-07-21 2023-05-16 扬州大学 超分子手性催化剂、其制备方法及其催化d-a反应的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
MXPA06002853A (es) 2003-09-11 2006-06-14 Kemia Inc Inhibidores citoquina.
US20090233950A1 (en) 2006-03-02 2009-09-17 Frederic Henri Jung Quinazoline derivatives
JP2009528336A (ja) 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キノリン誘導体
WO2007113548A1 (fr) 2006-04-06 2007-10-11 Astrazeneca Ab Dérivés de naphtyridine
WO2007113565A1 (fr) 2006-04-06 2007-10-11 Astrazeneca Ab Dérivés de la naphtyridine comme agents anti-cancéreux
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2404908B1 (fr) * 2009-02-27 2014-04-09 Teijin Pharma Limited Procédé de production de dérivés hétérocycliques substitués par un phényle par le biais d'un couplage à l'aide d'un catalyseur à métal de transition
EP2467137A1 (fr) 2009-08-19 2012-06-27 Ambit Biosciences Corporation Composés biaryles et procédés d utilisation de ceux-ci
DK2470173T3 (en) 2009-08-25 2016-06-06 Abraxis Bioscience Llc Combination therapy of nanoparticle composition of the taxane and the hedgehog inhibitors
CN102946881A (zh) 2010-04-23 2013-02-27 奇尼塔公司 抗病毒化合物
EP2651930B1 (fr) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Inhibiteurs biarylamide de production de leukotriènes
AU2013289938A1 (en) 2012-07-13 2015-01-29 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
UA115264C2 (uk) * 2013-03-15 2017-10-10 Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед Піридинові похідні як інгібітори реаранжованої у процесі трансфекції (ret) кінази
KR20160055170A (ko) * 2013-08-30 2016-05-17 암비트 바이오사이언시즈 코포레이션 바이아릴 아세트아미드 화합물 및 이의 사용 방법
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
US9783522B2 (en) * 2014-04-24 2017-10-10 Mitsubishi Tanabe Pharma Corporation 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof
PE20170677A1 (es) * 2014-09-10 2017-05-13 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
CA2960768A1 (fr) * 2014-09-10 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Derives de pyridone a titre d'inhibiteurs de la kinase rearrangee au cours de la transfection (ret)
WO2016061280A1 (fr) 2014-10-14 2016-04-21 La Jolla Institute Of Allergy & Immunology Inhibiteurs de la protéine tyrosine phosphatase de faible poids moléculaire et utilisations
CN104844589B (zh) 2014-12-26 2018-04-20 中国科学院合肥物质科学研究院 一种pi3k激酶抑制剂
WO2016127074A1 (fr) * 2015-02-06 2016-08-11 Blueprint Medicines Corporation Utilisation de dérivés 2-(pyridine-3-yl)-pyrimidine en tant qu'inhibiteurs de ret
JP6816100B2 (ja) 2015-07-16 2021-01-20 アレイ バイオファーマ、インコーポレイテッド ＲＥＴキナーゼ阻害物質としての置換ピラゾロ［１，５−ａ］ピリジン化合物
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物

Also Published As

Publication number Publication date
CY1123988T1 (el) 2022-05-27
DK3519398T3 (da) 2021-03-29
PH12019500480A1 (en) 2019-08-05
CN113788824A (zh) 2021-12-14
ECSP19030134A (es) 2019-08-30
PL3519398T3 (pl) 2021-06-28
JP2019534871A (ja) 2019-12-05
PT3519398T (pt) 2021-03-24
AU2017335242C1 (en) 2021-12-09
RS61640B1 (sr) 2021-04-29
JP7098609B2 (ja) 2022-07-11
EP3828178A1 (fr) 2021-06-02
US20210163464A1 (en) 2021-06-03
SMT202100315T1 (it) 2021-07-12
UA123964C2 (uk) 2021-06-30
MA46337A (fr) 2019-08-07
CN110036007B (zh) 2021-10-15
EA201990833A1 (ru) 2019-10-31
CL2019000844A1 (es) 2019-06-07
CA3035860A1 (fr) 2018-04-05
SG11201901937WA (en) 2019-04-29
US20200039974A1 (en) 2020-02-06
HRP20210447T1 (hr) 2021-07-23
SI3519398T1 (sl) 2021-07-30
KR20190086442A (ko) 2019-07-22
ES2868748T3 (es) 2021-10-21
CO2019004034A2 (es) 2019-07-10
PE20190805A1 (es) 2019-06-10
LT3519398T (lt) 2021-05-10
EP3519398A1 (fr) 2019-08-07
AU2021261899A1 (en) 2021-12-02
BR112019006047A2 (pt) 2019-06-25
KR102520543B1 (ko) 2023-04-10
US10851092B2 (en) 2020-12-01
EP3519398B1 (fr) 2021-02-24
AU2017335242A1 (en) 2019-05-02
WO2018060714A1 (fr) 2018-04-05
MX2019003747A (es) 2019-09-19
MD3519398T2 (ro) 2021-05-31
IL265630A (en) 2019-05-30
IL265630B (en) 2021-10-31
JP2018052878A (ja) 2018-04-05
ZA201902232B (en) 2022-12-21
CN110036007A (zh) 2019-07-19
MA54910A (fr) 2022-04-13
EA037103B1 (ru) 2021-02-05
HUE054824T2 (hu) 2021-10-28
AU2017335242B2 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
MA46337B1 (fr) Composé de pyridine
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
MA52948B1 (fr) Composés
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
EA201890473A1 (ru) Гетероарильные производные в качестве ингибиторов parp
CR20200376A (es) Inhibidores de cd73
MA38454B1 (fr) Inhibiteurs de protéines kinases
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
EA202193015A1 (ru) Ингибиторы cdk
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MX373786B (es) Derivados de pirimidin-2,4-diamina para el tratamiento de cáncer.
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
EA201991884A3 (ru) Ингибиторы g12c kras
MA39983B1 (fr) Dérivés de carboxamide
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
NZ746906A (en) Oxaborole esters and uses thereof
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MX2021007258A (es) Composiciones de esparsentan amorfas.
EP4438127A3 (fr) Inhibition de la protéine associée à l'ataxie télangiectasie et à rad3 (atr)
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain